Literature DB >> 6245699

Pyrophosphate analogues as inhibitors of herpes simplex virus type 1 DNA polymerase.

B Eriksson, A Larsson, E Helgstrand, N G Johansson, B Oberg.   

Abstract

Twenty nine pyrophosphate analogues have been tested for their ability to inhibit herpes simplex virus type 1 (HSV-1) DNA polymerase activity. The structural requirements for active inhibitors and their mechanism of action have been investigated. Active compounds had two negatively charged groups at close proximity. The most active compounds contained free phosphono and/or carboxyl groups. Apart from phosphonoformate and phosphonoacetate, which were strong inhibitors, some other analogues, 2-phosphonopropionate, 2-phenylphosphonoacetate, oxalate, carbonyldiphosphate, methanehydroxy-diphosphonate and hypophosphate also inhibited the HSV-1 DNA polymerase activity. With the exception of hypophosphate the tested compounds inhibited the activity of calf thymus DNA polymerase alpha to a lesser extent than the activity of the HSV-1 DNA polymerase. All inhibitors gave linear uncompetitive inhibition of HSV-1 DNA polymerase with activated DNA as variable substrate. With the four deoxynucleoside triphosphates as variable substrates all inhibitors except hypophosphate gave linear non-competitive inhibition patterns. Hypophosphate caused a more competitive type of inhibition. The inhibition constants for the active compounds have been determined. Phosphonoformate, phosphonoacetate, methanehydroxydiphosphonate and hypophosphate also inhibited HSV-1 plaque formation in cell culture.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6245699     DOI: 10.1016/0005-2787(80)90220-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  20 in total

1.  Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir.

Authors:  D M Coen; D J Goldstein; S K Weller
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 2.  Resistance of herpesviruses to antiviral drugs.

Authors:  P A Chatis; C S Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

3.  Purification of Epstein-Barr virus DNA polymerase from P3HR-1 cells.

Authors:  B Kallin; L Sternås; A K Saemundssen; J Luka; H Jörnvall; B Eriksson; P Z Tao; M T Nilsson; G Klein
Journal:  J Virol       Date:  1985-05       Impact factor: 5.103

4.  Activity of the cytomegalovirus genome in the presence of PPi analogs.

Authors:  B Wahren; U Rudén; H Gadler; B Oberg; B Eriksson
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

5.  PPi analogs as inhibitors of human T-lymphotropic virus type III reverse transcriptase.

Authors:  L Vrang; B Oberg
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

6.  Concentration-dependent effects of foscarnet on the cell cycle.

Authors:  K Stenberg; S Skog; B Tribukait
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

7.  Unusual regulation of expression of the herpes simplex virus DNA polymerase gene.

Authors:  K K Wobbe; P Digard; D Staknis; D M Coen
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

8.  Rapid typing of herpes simplex virus based on immunological specificity of viral thymidine kinase and typing according to sensitivity to iododeoxyuridine.

Authors:  J S Gronowitz; C F Källander; S Jeansson; J Wallin
Journal:  J Clin Microbiol       Date:  1982-03       Impact factor: 5.948

9.  Mutually exclusive inhibition of herpesvirus DNA polymerase by aphidicolin, phosphonoformate, and acyclic nucleoside triphosphates.

Authors:  K B Frank; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

10.  Differential inhibition of DNA polymerase and RNase H activities of the reverse transcriptase by phosphonoformate.

Authors:  M Margalith; H Falk; A Panet
Journal:  Mol Cell Biochem       Date:  1982-03-19       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.